Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16273
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrasso, Carole-
dc.contributor.authorAnaka, Matthew-
dc.contributor.authorHofmann, Oliver-
dc.contributor.authorSompallae, Ramakrishna-
dc.contributor.authorBroadley, Kate-
dc.contributor.authorHide, Winston-
dc.contributor.authorBerridge, Michael V-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorBehren, Andreas-
dc.contributor.authorMcConnell, Melanie J-
dc.date2016-09-09-
dc.date.accessioned2016-09-15T06:28:18Z-
dc.date.available2016-09-15T06:28:18Z-
dc.date.issued2016-09-09-
dc.identifier.citationBMC Cancer 2016; 16(1): 726en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16273-
dc.description.abstractBACKGROUND: The heterogeneity and tumourigenicity of metastatic melanoma is attributed to a cancer stem cell model, with CD133 considered to be a cancer stem cell marker in melanoma as well as other tumours, but its role has remained controversial. METHODS: We iteratively sorted CD133+ and CD133- cells from 3 metastatic melanoma cell lines, and observed tumourigenicity and phenotypic characteristics over 7 generations of serial xeno-transplantation in NOD/SCID mice. RESULTS: We demonstrate that iterative sorting is required to make highly pure populations of CD133+ and CD133- cells from metastatic melanoma, and that these two populations have distinct characteristics not related to the cancer stem cell phenotype. In vitro, gene set enrichment analysis indicated CD133+ cells were related to a proliferative phenotype, whereas CD133- cells were of an invasive phenotype. However, in vivo, serial transplantation of CD133+ and CD133- tumours over 7 generations showed that both populations were equally able to initiate and propagate tumours. Despite this, both populations remained phenotypically distinct, with CD133- cells only able to express CD133 in vivo and not in vitro. Loss of CD133 from the surface of a CD133+ cell was observed in vitro and in vivo, however CD133- cells derived from CD133+ retained the CD133+ phenotype, even in the presence of signals from the tumour microenvironment. CONCLUSION: We show for the first time the necessity of iterative sorting to isolate pure marker-positive and marker-negative populations for comparative studies, and present evidence that despite CD133+ and CD133- cells being equally tumourigenic, they display distinct phenotypic differences, suggesting CD133 may define a distinct lineage in melanoma.en_US
dc.subjectAC133 antigenen_US
dc.subjectMelanomaen_US
dc.titleIterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populationsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMC Canceren_US
dc.identifier.affiliationLudwig Institute for Cancer Research, Olivia Newton-John Cancer & Wellness Centre, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationHarvard T.H. Chan School of Public Health, Boston, MA, USAen_US
dc.identifier.affiliationHarvard Stem Cell Institute, Holyoke Center, Cambridge, MA, USAen_US
dc.identifier.affiliationSheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UKen_US
dc.identifier.affiliationMalaghan Institute of Medical Research, Wellington, New Zealanden_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27613604en_US
dc.identifier.doi10.1186/s12885-016-2759-2en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherCebon, Jonathan S
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
art%3A10.1186%2Fs12885-016-2759-2.pdf3.67 MBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

12
checked on Sep 26, 2024

Download(s)

14
checked on Sep 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.